|Articles|August 21, 2009

Extending Calibrations for Near-Infrared Assay of Tablets Using Synthetic Modeling and Variance from Placebos - Foss Whitepaper

External Link - article-620797.pdf

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Scientist comparing two vials in laboratory research setting | Image Credit: ©Phimwilai -stock.adobe.com

Overcoming Formulation Challenges for Biosimilars

ByCynthia A. Challener

May 1st 2026

Amyloid plaques in Alzheimer's disease | Image Credit: ©Artur -stock.adobe.com

European Biotechs Impacting Treatment of Alzheimer’s Disease

ByCheryl Barton

February 12th 2026

FAQ: Key Innovations in Drug Delivery and Formulation in 2025

ByPatrick Lavery

December 8th 2025

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | Image Credit: © Tada Images - stock.adobe.com

FDA, Duke University Planning Epinephrine Access Workshop for December

ByPatrick Lavery

November 24th 2025

Dosage Form Innovations: A CPHI Frankfurt Conversation with Lonza’s Frank Romanski, Part One

ByPatrick Lavery

October 31st 2025

Extending Calibrations for Near-Infrared Assay of Tablets Using Synthetic Modeling and Variance from Placebos - Foss Whitepaper

Related Content

Overcoming Formulation Challenges for Biosimilars

European Biotechs Impacting Treatment of Alzheimer’s Disease

FAQ: Key Innovations in Drug Delivery and Formulation in 2025

FDA, Duke University Planning Epinephrine Access Workshop for December

Dosage Form Innovations: A CPHI Frankfurt Conversation with Lonza’s Frank Romanski, Part One

Trending on Pharmaceutical Technology

PharmTech Weekly Roundup—June 5, 2026

Generic GLP-1s Enter Canadian Market

Tom Sellig on CDMO Innovation and US Manufacturing Growth

Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance

FDA Guidance for Accelerating Gene Therapies for Rare Diseases